文献速递淋巴瘤

儿童IV期霍奇金淋巴瘤表现模式与结局:COG AHOD1331试验报告

Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial.
PubMed 文献 · Br J Haematol · 2026-07-08

AHOD1331试验纳入340例2-21岁高危经典型霍奇金淋巴瘤(cHL)IV期患者,随机接受ABVE-PC或Bv-AVEPC方案。仅肺受累者4年PFS最高(88.6%),仅骨髓受累者最低(71.9%)。Bv-AVEPC较ABVE-PC改善所有IV期患者PFS(HR 0.53,90%CI 0.33-0.85),但仅骨髓受累者无PFS获益。

要点

  • IV期cHL中仅肺受累者4年PFS达88.6%,仅骨髓受累者最低为71.9%。
  • Bv-AVEPC较ABVE-PC改善IV期cHL总体PFS(HR 0.53,90%CI 0.33-0.85)。
  • 仅骨髓受累的IV期cHL患者未从Bv-AVEPC中获得PFS获益。

核心结论

  • 在儿童IV期cHL中,Bv-AVEPC较ABVE-PC改善大多数表现模式的PFS,但仅骨髓受累者无PFS获益。

研究设计与样本

  • AHOD1331(NCT02166463)随机试验纳入340例2-21岁高危cHL(IIB伴巨块/IIIB/IVA/IVB)患者,其中IV期340例(中位年龄15岁),173例(51%)接受ABVE-PC,167例(49%)接受Bv-AVEPC。

主要发现

  • 仅肺受累者4年PFS最高为88.6%,仅骨髓受累者最低为71.9%。
  • Bv-AVEPC较ABVE-PC改善所有IV期患者PFS(HR 0.53,90%CI 0.33-0.85)。
  • Bv-AVEPC在仅肺受累和仅骨受累亚组中改善PFS。
  • 仅骨髓受累者中未观察到Bv-AVEPC的PFS获益。

临床怎么用

  • 儿童IV期cHL可依据远处结外受累部位(肺、骨、骨髓等)评估预后并指导治疗选择。
  • Bv-AVEPC可作为多数IV期cHL表现模式(除仅骨髓受累外)的PFS改善方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes for high-risk paediatric classic Hodgkin lymphoma (cHL) improved with the addition of brentuximab vedotin (Bv) to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVEPC) chemotherapy. We evaluated the prognostic implications of distant extra-nodal sites contributing to stage IV disease. On AHOD1331 (NCT02166463), patients aged 2-21 years with high-risk cHL (stage IIB with bulk/IIIB/IVA/IVB) were randomized to 5 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (ABVE-PC) versus Bv-AVEPC. Patients with stage IV disease, determined by protocol-defined and centrally reviewed Positron Emission Tomography - Computed Tomography (PET-CT), were identified. Baseline characteristics and progression-free survival (PFS) were compared by pattern of stage IV involvement (lung, bone, bone marrow, multiple sites and others). A total of 340 patients (median age 15 years) with stage IV disease were included. Of these patients, 173 (51%) received ABVE-PC and 167 (49%) Bv-AVEPC. PFS was highest with lung-only involvement (4-year PFS 88.6%) and lowest with bone marrow-only involvement (4-year PFS 71.9%). Compared to ABVE-PC, Bv-AVEPC improved PFS among all stage IV patients (hazard ratio [HR] 0.53, 90% confidence interval (CI) 0.33-0.85) and in the lung-only and bone-only subgroups. However, no PFS benefit was observed in those with bone marrow-only involvement. Among paediatric patients with stage IV cHL, Bv-AVEPC improved PFS across most patterns of stage IV disease, except in those with bone marrow involvement. These results will guide efforts to improve outcomes among children with stage IV cHL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Casey DL, Renfro LA, Wu Y, et al. Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial. Br J Haematol. 2026. PMID: 42419755. doi:10.1111/bjh.70625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。